OVID THERAPEUTICS DL-,001

Ovid Therapeutics presented at the H.C. Wainwright conference its focus strategy on brain disorders driven by neuronal hyperexcitability, centered on two lead programs: OV329 for epilepsy and OV4071, the first oral direct KCC2 activator. Management said OV329 shows a strong safety profile and is expected to report photosensitivity data in the coming months and phase II results in about a year; OV4071 is in phase I, a ketamine challenge is planned before year‑end, and a phase II program for acute schizophrenia is scheduled for mid‑2025. Financial figures were not discussed; management emphasized the platform ambitions, biomarker‑driven development and multiple near‑term proof‑of‑concept catalysts. » Más en de.investing.com

At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » Más en de.investing.com

Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » Más en finance.yahoo.com